- Home
- LENZ
as 11-21-2024 4:00pm EST
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | DEL MAR |
| Market Cap: | 886.2M | IPO Year: | 2021 |
| Target Price: | $35.40 | AVG Volume (30 days): | 157.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.12 - $38.93 | Next Earning Date: | 11-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest LENZ Therapeutics Inc. Common Stock News
LENZ Breaking Stock News: Dive into LENZ Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
LENZ Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
15 days ago
LENZ Therapeutics Reports Third Quarter 2024 Financial Results
GlobeNewswire
22 days ago
LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024
GlobeNewswire
25 days ago
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100
TipRanks
a month ago
Lenz Therapeutics announces FDA acceptance of NDA for LNZ100
GlobeNewswire
a month ago
LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia
GlobeNewswire
2 months ago
LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences
Simply Wall St.
2 months ago
LENZ Therapeutics Insiders Up US$178k On US$551.1k Investment
Compare LENZ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LENZ LENZ Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.